Provided by Tiger Fintech (Singapore) Pte. Ltd.

ESG Concept

2,762.60
-52.2859-1.86%
Number of Gainers:7
Number of Losers:36
Number of Flat:1
PE:- -
High:2,815.18
Open:2,815.18
Low:2,754.91
Close:2,814.88
Loading ...

BRIEF-Vertex Announces UK Mhra Approval Of Alyftrek

Reuters
·
08 Mar

Why Comfort Systems USA Stock Slid 17% Last Month

Motley Fool
·
08 Mar

BlackRock, Inc. (BLK): Jim Cramer Says, ‘It’s Worth Much More Than It’s Selling For!’

Insider Monkey
·
08 Mar

Vertex Pharmaceuticals Gets UK Regulatory Approval for Alyftrek to Treat Cystic Fibrosis

MT Newswires Live
·
07 Mar

FactSet Research Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
07 Mar

BUZZ-Deutsche Bank initiates coverage on some US trucking firms

Reuters
·
07 Mar

Vertex Pharmaceuticals announces MHRA approval of ALYFTREK for CF

TIPRANKS
·
07 Mar

Vertex Pharmaceuticals Inc - Working With Nice and Nhs for Alyftrek Access

THOMSON REUTERS
·
07 Mar

Vertex Announces UK Mhra Approval of Alyftrek® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class Cftr Modulator for the Treatment of Cystic Fibrosis

THOMSON REUTERS
·
07 Mar

Do Its Financials Have Any Role To Play In Driving Fastenal Company's (NASDAQ:FAST) Stock Up Recently?

Simply Wall St.
·
07 Mar

THE MEXICO FUND, INC. DECLARES DISTRIBUTION

PR Newswire
·
07 Mar

COTY Stock Plunges More Than 25% in 3 Months: What Should You Do?

Zacks
·
07 Mar

Is the Options Market Predicting a Spike in Applied Materials (AMAT) Stock?

Zacks
·
07 Mar

Is it Worth Adding ResMed Stock to Your Portfolio Now?

Zacks
·
07 Mar

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

GlobeNewswire
·
07 Mar

Vertex Pharmaceuticals' Triple Combination Cystic Fibrosis Therapy Alyftrek Receives Approval in UK

MT Newswires Live
·
07 Mar